Go Pro
→ Someone just dumped the biggest gold fund. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.29
$253.63
$186.05
▼
$282.15
$15.80B0.39545,017 shs363,772 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.50
$78.85
$46.81
▼
$93.42
$15.93B0.962.30 million shs1.74 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.70
$60.67
$49.26
▼
$70.98
$12.91B0.242.31 million shs1.59 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$26.10
$23.68
$11.92
▼
$27.31
$4.87B1.071.98 million shs1.18 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+1.93%-0.22%+2.53%+30.36%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+2.05%-3.00%+17.91%+66.06%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%-0.98%+12.42%+23.31%+13.86%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%+1.56%+6.79%+50.26%+107.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.29
$253.63
$186.05
▼
$282.15
$15.80B0.39545,017 shs363,772 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.50
$78.85
$46.81
▼
$93.42
$15.93B0.962.30 million shs1.74 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.70
$60.67
$49.26
▼
$70.98
$12.91B0.242.31 million shs1.59 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$26.10
$23.68
$11.92
▼
$27.31
$4.87B1.071.98 million shs1.18 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+1.93%-0.22%+2.53%+30.36%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+2.05%-3.00%+17.91%+66.06%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%-0.98%+12.42%+23.31%+13.86%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%+1.56%+6.79%+50.26%+107.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$300.3318.57% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7923.67% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.75
Moderate Buy$88.8333.17% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.87
Moderate Buy$34.4231.86% Upside

Current Analyst Ratings Breakdown

Latest DYN, BBIO, ASND, and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$60.00 ➝ $59.00
8/17/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/17/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $88.00
8/17/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$105.00 ➝ $111.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $341.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$345.00 ➝ $329.00
(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.40N/AN/A($2.97) per share-85.28
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$713.07M22.34N/AN/A($10.77) per share-7.57
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.41B3.79$2.85 per share23.38$31.68 per share2.11
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8919.6523.72N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37180.2712.350.482.14%5.32%3.69%10/26/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)

Latest DYN, BBIO, ASND, and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100186.75 million169.08 millionOptionable

Recent News About These Companies

Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 22 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975683
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts
August 22 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/dyne-therapeutics-inc-nasdaqdyn-receives-average-rating-of-moderate-buy-from-analysts-2026-08-22/
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN
August 21 at 4:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-buys-49641-shares-of-dyne-therapeutics-inc-dyn-2026-08-21/
Equities Analysts Offer Predictions for DYN Q3 Earnings
August 21 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973604
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348792/0/en/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Q3 EPS Forecast for Dyne Therapeutics Decreased by Analyst
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-forecast-for-dyne-therapeutics-decreased-by-analyst-2026-08-19/
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-acquires-shares-of-53200-dyne-therapeutics-inc-dyn-2026-08-19/
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 2,160,516 Shares of Stock
August 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30968564
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 426,412 Shares
August 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30968576
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-flputnam-investment-management-co-makes-new-investment-in-dyne-therapeutics-inc-dyn-2026-08-18/
Dyne Therapeutics (NASDAQ:DYN) Director Sells 426,412 Shares
August 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-dyn-insider-buying-and-selling-2026-08-18/
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-aegis-wealth-management-llc-invests-333-million-in-dyne-therapeutics-inc-dyn-2026-08-18/
Jason Rhodes Sells 426,412 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jason-rhodes-sells-426412-shares-of-dyne-therapeutics-nasdaqdyn-stock-2026-08-17/
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-dyne-therapeutics-nasdaqdyn-director-sells-5401290000-in-stock-2026-08-17/
Bank of America Corp DE Has $26.17 Million Holdings in Dyne Therapeutics, Inc. $DYN
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-2617-million-holdings-in-dyne-therapeutics-inc-dyn-2026-08-17/
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week High - Here's What Happened
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/dyne-therapeutics-nasdaqdyn-hits-new-52-week-high-heres-what-happened-2026-08-11/
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-1724-million-holdings-in-dyne-therapeutics-inc-dyn-2026-08-08/
Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
August 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/DYN/pressreleases/3684969/raymond-james-reaffirms-their-buy-rating-on-dyne-therapeutics-dyn/
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week High - Should You Buy?
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/dyne-therapeutics-nasdaqdyn-reaches-new-52-week-high-should-you-buy-2026-08-05/
Bank of New York Mellon Corp Buys 48,119 Shares of Dyne Therapeutics, Inc. $DYN
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-buys-48119-shares-of-dyne-therapeutics-inc-dyn-2026-08-04/
Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dyne-therapeutics-inc-dyn-shares-purchased-by-renaissance-technologies-llc-2026-08-03/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
L3Harris logo on a panel with a satellite, drone, camera sensor, and network icons against a sunset sky.
L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
By Thomas Hughes | July 31, 2026
Autonomous mobile robots carrying storage bins move through an automated factory production line with illuminated blue accents.
3 Robotics Stocks Under $10: Value, Momentum, or Bet?
By Chris Markoch | August 17, 2026
Medical imaging scanner with exposed internal components being assembled in a manufacturing facility with computer workstations.
Inside Teledyne's Bold Bet on the Future of Medical Imaging
By Jeffrey Neal Johnson | August 14, 2026
A rubber stamp reading "Dividends" rests beside a stamped document, stacked coins, and US currency.
3 Closed-End Funds to Maximize Dividend Payments
By Nathan Reiff | August 23, 2026
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$253.29 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$81.50 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$66.70 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$26.10 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas